Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: Impact of weight reduction

Nutrition and Diabetes

Volumn 5, Issue , 2015, Pages

  Lesna J ^a,b   Ticha A ^a   Hyspler R ^a   Musil, F ^a   Blaha V ^a   Sobotka, L ^a,b   Zadak Z ^a   Smahelova A ^a,b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CARBOHYDRATE; HIGH DENSITY LIPOPROTEIN; LATHOSTEROL; PROTEIN OMENTIN 1; SQUALENE; STEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABSORPTION; ADULT; ARTICLE; BODY MASS; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84946563175     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2015.33     Document Type: Article

References (30)

1. Conway B, Miller RG, Costacou T, FriedL, Kelsey S, Evans RW, et al. Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med 2010; 27: 398-404.
2. Browne D, Meeking D, Shaw K, Cummings M. Endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes, pathogenesis and identification. Br J Diabetes Vasc Dis 2003; 3: 27-34.
3. Tan B K, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity and cardiovascular disease. Trends Cardiovasc Med 2010; 20: 143-148.
4. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
5. Lago F, Gómez R, Gómez-Reino JJ, Dieguez C, Gualillo O. Adipokines as novel modulators of lipid metabolism. Trends Biochem Sci 2009; 34: 500-510.
6. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-1261.
7. De Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661.
8. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon M J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
9. Stejskal D, Ruzicka V, Adamovska S, Jurakova R, Proskova J, Jedelsky L, et al. Adiponectin concentrations as a criterion of metabolic control in persons with type2 diabetes mellitus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003; 147: 167-172.
10. Tan B K, Adya R, Farhatullah S, Lewandowski K C, Hare P O, Lehnert H, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome. Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-808.
11. Yilmaz Y, Yonal O, Kurt R, Alhdab YO, Eren F, Ozdogan O, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46: 91-97.
12. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010; 59: 3023-3031.
13. Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K, et al. Human intelectin is a novel soluble lectin that recognises galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 2001; 276: 23456-23463.
14. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011; 408: 339-343.
15. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilatation in rat isolated blood vessels. Biochem Biophys Res Commun 2010; 393: 668-672.
16. Duan XY, Xie PL, Ma YL, Tang SY. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids 2011; 41: 1223-1231.
17. Tan BK, Pua S, Syed F, Lewandowski KC, O'Hare JP, Randeva HS. Decreased plasma omentin-1 levels in diabetes mellitus Type 1. Diabet Med 2008; 25: 1254-1255.
18. Simonen P, Gylling H, Howard A, Miettinen T A. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000; 72: 82-88.
19. Šmahelová A, Zadák Z, Hyšpler R, Haas T. An importance of vegetable sterols in diabetics (in Czech). Vnit? Lék 2004; 50: 147-152.
20. Moreno-Navarrete J M, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G, et al. Circulating omentin concentration increases after weight loss. Nutr Metab 2010; 7: 27.
21. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011; 34: 307-310.
22. Auget T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011; 12: 60.
23. Pan HY, Guo L, Li Q. Changes in serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clinical Prac 2010; 88: 29-33.
24. Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 257-263.
25. Saremi A, Ascghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci 2010; 28: 993-998.
26. Barth S, Klein P, Horbach T, Dotsch J, Rauh M, Rascher W, et al. Expression of Neuropeptide Y, Omentin and Visfatin in Visceral and Subcutaneous Adipose Tissues in Humans: Relation to Endocrine and Clinical Parameters. Obes Facts 2010; 3: 245-251.
27. Moreno-Navarrete Jmm, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity (Silver Spring) 2011; 19: 1552-1559.
28. Ji-Yin Z, Ch Lawrence, Shi-Wen Z., Omentin. Linking Metabolic Syndrome and Cardiovascular Disease. Curr Vasc Pharmacol 2014; 12: 136-143.
29. Yu D Omentin activates AMP - activated protein kinase and plays a role in energy metabolism and immune response. PhD dissertation. Molecular Medicine. University of Maryland, Baltimore, MD, USA, 2011.
30. Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, et al.. Omentin prevents myocardial ischaemic injury through AMP-activated protein kinase - and Akt-dependent mechanisms. J Am Coll Cardiol 2014; 63: 2722-2733.